| Identification | Back Directory | [Name]
ILUPZUOBHCUBKB-UHFFFAOYSA-N | [CAS]
343321-96-0 | [Synonyms]
ILUPZUOBHCUBKB-UHFFFAOYSA-N
Propanoic acid, 2-methyl-2-[4-[[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-
lipid,LDLc,GW-590735,GW 590735,HDLc,Peroxisome proliferator-activated receptors,GW590735,PPAR,imbalance,Inhibitor,inhibit,triglycerides,dyslipidemia | [Molecular Formula]
C23H21F3N2O4S | [MDL Number]
MFCD12912339 | [MOL File]
343321-96-0.mol | [Molecular Weight]
478.48 |
| Chemical Properties | Back Directory | [Melting point ]
130-131 °C(Solv: toluene (108-88-3)) | [density ]
1.342±0.06 g/cm3(Predicted) | [solubility ]
DMF: 30 mg/ml
DMSO: 30 mg/ml
Ethanol: 30 mg/mlPBS (pH 7.2): 0.25 mg/ml | [form ]
Solid | [pka]
3.24±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia[1]. | [in vivo]
GW 590735 (0.5-5 mg/kg; orally twice a day for 5 days) is able to lower LDLc and triglycerides (TG) and increase HDL cholesterol in the Apo-A-I-transgenic mouse model (male C57BL/6 mice transgenic for human ApoA-I)[1].
GW 590735 (intravenous administration; 2.7 mg/kg; rat) treatment shows Cl, Vd, T1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively[1].
GW 590735 (intravenous administration; 2 mg/kg; dog) treatment shows Cl, Vd, T1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively[1]. | [References]
[1] Sierra ML, et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007;50(4):685-695. DOI:10.1021/jm058056x |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|